Download MendeleySynthesis and biological evaluation of biaryl alkyl ethers as inhibitors of IDO1.
Markwalder, J.A., Balog, A.J., Williams, D.K., Nara, S.J., Reddy, R., Roy, S., Kanyaboina, Y., Li, X., Johnston, K., Fan, Y., Lewis, H., Marsilio, F., Yan, C., Critton, D., Newitt, J.A., Traeger, S.C., Wu, D.R., Jure-Kunkel, M.N., Jayaraman, L., Lin, T.A., Sinz, M.W., Hunt, J.T., Seitz, S.P.(2023) Bioorg Med Chem Lett 88: 129280-129280
- PubMed: 37054759
- DOI: https://doi.org/10.1016/j.bmcl.2023.129280
- Primary Citation of Related Structures:
8FUR - PubMed Abstract:
Starting from the dialkylaniline indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor lead 3 (IDO1 HeLa IC 50 = 7.0 nM), an iterative process of synthesis and screening led to cyclized analog 21 (IDO1 HeLa IC 50 = 3.6 nM) which maintained the high potency of 3 while addressing issues of lipophilicity, cytochrome P450 (CYP) inhibition, hERG (human potassium ion channel Kv11.1) inhibition, Pregnane X Receptor (PXR) transactivation, and oxidative metabolic stability. An x-ray crystal structure of a biaryl alkyl ether 11 bound to IDO1 was obtained. Consistent with our earlier results, compound 11 was shown to bind to the apo form of the enzyme.
Organizational Affiliation:
Research & Development, Bristol Myers Squibb, Route 206 & Province Line Road, Princeton, NJ 08543, United States. Electronic address: itr114@gmail.com.
